PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 2018 January; 62(1): e01124-17.
Published online 2017 December 21. doi:  10.1128/AAC.01124-17
PMCID: PMC5740369

Correction for Pandharkar et al., “Studies on the Antileishmanial Mechanism of Action of the Arylimidamide DB766: Azole Interactions and Role of CYP5122A1”

AUTHOR CORRECTION

Volume 58, no. 8, 4682–4689, 2014, https://doi.org/10.1128/AAC.02405-14. Due to ongoing work with arylimidamide-azole combinations, we reexamined the data summarized in Table 2 from this publication. Errors were found in the IC50 value reported for DB766 against L. donovani axenic amastigotes in experiment 2 and in the fitting of some of the individual curves used to arrive at the results expressed in the left-hand side of Table 2. Reanalysis of the original data resulted in the determination of IC50 values of 0.40 μM and 1.7 μM for DB766, IC50 values of 7.3 and 10 μM for posaconazole, and mean ∑FIC values of 0.70 ± 0.17 and 0.44 ± 0.06 in experiments 1 and 2, respectively. In the recalculation of the IC50 value of DB766 in experiment 1, the data point at the lowest concentration of DB766 was excluded due to an absorbance value similar to the no-cell control (likely due to evaporation in the edge well). All IC50 values were recalculated as absolute IC50s to account for dose-response curves where the upper asymptotes did not reach the positive control (no drug) values. The senior author apologizes for the need for this correction and takes responsibility for it.


Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)